cytochrome P450 family 11 subfamily B member 1Genealiases: CPN1 · CYP11B · FHI · P450C11
Q-omics provides the consensus-scored CYP11B1 profile across patient tissues and cancer cell-line models. CYP11B1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CYP11B1 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, CYP11B1 RNA expression shows 6,550 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, and LSCC as cancer lineages where CYP11B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP11B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP11B1 survival associations across molecular data types. CYP11B1 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP11B1 RNA expression–survival associations across cancer types. High CYP11B1 expression shows unfavorable associations in BRCA, LIHC, THYM, KIRC, TGCT and LUSC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CYP11B1 RNA expression.
This table summarizes CYP11B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYP11B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP11B1 shows higher tumor expression in BRCA, STAD, LUAD and KIRC. The BRCA box plot shows higher CYP11B1 RNA expression in tumor versus normal tissue (log2 FC = +0.006, t-test p = .002).
This table shows molecular features associated with CYP11B1 in patient tissues and cancer cell lines. In patient samples, CYP11B1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP11B1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
